Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 680

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 680
---
 for Issuance under Equity Compensation Plans 

Reference
is made to “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters—Securities
Authorized for Issuance under Equity Compensation Plans” for the information required by this item.

Recent
Sales of Unregistered Securities

On
June 12, 2024, the Company agreed to issue up to an aggregate of 140,000 shares of Common Stock to a vendor in considerations
for the services provided by the vendor to the Company, with 51,187 shares issued between June 1, 2024 and December 31, 2024

On
August 12, 2024, the Company agreed to issue 10,000 shares of Common Stock to a vendor in exchange for outstanding invoices
related to services provided by the vendor to the Company.

On
October 22, 2024, the Company agreed to issue up to an aggregate of 76,667 shares of Common Stock to three vendors in considerations
for the services provided by the vendor to the Company.

Also
on October 22, 2024, the Company granted a different vendor options to purchase up to an aggregate of 50,000 shares of Common
Stock at a grant price of $0.73 per share.

On
November 18, 2024, the Company agreed to issue up to 25,000 shares of Common Stock to a vendor in considerations for
the services provided by the vendor to the Company.

67 

Between September 1, 2024 and December
31, 2024, we issued and sold an aggregate of 155,953 shares of Common Stock to Tikkun pursuant to the CEF Purchase Agreement at
an average price per share of $0.70, resulting in aggregate gross proceeds to the Company of $108,552. 

The
offers and sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon
Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder, or Rule 701 promulgated under Section 3(b) of the
Securities Act, as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating
to compensation as provided under Rule 701. The recipients of the above securities represented their intentions to acquire the
securities for investment only and not with a view to or for sale in connection with any distribution thereof